A phase II trial of docetaxel and vinorelbine in patients with hormone-refractory prostate cancer
| Autor: | Lixian Jin, Kamakshi V. Rao, Terry Capanna, Mary B. Todd, S. Doyle-Lindrud, Nisha Dave, Susan Goodin, Elizabeth Engle, Robert S. DiPaola, Michael P. Kane |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Oncology
Adult Male Cancer Research medicine.medical_specialty Antineoplastic Agents Hormonal medicine.medical_treatment Docetaxel Filgrastim Adenocarcinoma Toxicology Vinorelbine Vinblastine Prostate cancer Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Pharmacology (medical) Infusions Intravenous Aged Pharmacology Aged 80 and over Mitoxantrone Chemotherapy business.industry Prostatic Neoplasms Middle Aged medicine.disease Chemotherapy regimen Surgery Drug Resistance Neoplasm Injections Intravenous Taxoids business Febrile neutropenia medicine.drug |
| Zdroj: | Cancer chemotherapy and pharmacology. 56(2) |
| ISSN: | 0344-5704 |
| Popis: | Recent studies of docetaxel have demonstrated improved survival over mitoxantrone and prednisone in patients with hormone-refractory prostate cancer (HRPC), supporting the study of novel docetaxel-containing regimens as primary therapy or following initial docetaxel-based therapy. To evaluate the combination of docetaxel and vinorelbine in the treatment of patients with HRPC, 40 patients with proven adenocarcinoma of the prostate with progressive metastatic disease despite androgen ablation were enrolled onto this phase II trial. Patients were treated with docetaxel 60 mg/m2 on day 1 and vinorelbine 15 mg/m2 on days 1 and 8 of a 21-day cycle. All patients received dexamethasone 8 mg twice daily for 4 days starting 1 day prior to the docetaxel infusion. After the first three patients were enrolled, filgrastim was added on days 2–6 and 9–13. Of the 40 patients enrolled, 19 had no prior chemotherapy and 21 had received at least one prior chemotherapy regimen. Of the 19 patients without prior chemotherapy and the 21 with prior chemotherapy, 7 (37%) and 6 (29%) , respectively, demonstrated a decrease in prostate specific antigen by >50% maintained for at least 4 weeks. Out of eight patients with measurable disease, one achieved a partial response and four demonstrated stable disease. There was one patient with deep vein thrombosis, and febrile neutropenia was noted in only three patients after the protocol was modified to include filgrastim support. The combination of docetaxel and vinorelbine with filgrastim was well tolerated and active against HRPC in patients with or without prior chemotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink